Clinical trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2409021 After Escalating Single Oral Dose Administration in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
NCT01606371 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2409021 After Escalating Single Oral Dose Administration in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2007
- Completion date
- October 31, 2007
- Enrollment
- 32 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.